BioMarin Pharmaceutical

Company BMRN

Last mentioned: 2d ago

Stories mentioning BioMarin Pharmaceutical 2

pharma Neutral

Summit Therapeutics Leads High-Stakes Biotech Q4 Earnings Wave

Summit Therapeutics and its mid-cap biotech peers are set to report Q4 2025 results, with investor focus centered on Summit's ivonescimab commercialization path and BioMarin's Voxzogo expansion. These reports will serve as a critical barometer for the sector's ability to transition from R&D-heavy pipelines to sustainable commercial growth.

4 sources
pharma Bullish

PKU Market Set for Decade of Growth as Innovative Therapies Target Unmet Needs

The global Phenylketonuria (PKU) market is projected to expand significantly through 2034, fueled by a robust pipeline of next-generation therapies and enhanced diagnostic screening. With the United States leading in diagnosed prevalence, major players like BioMarin, PTC Therapeutics, and Jnana are racing to address the metabolic limitations of current standard-of-care treatments.

3 sources